Stem cell therapy Glendale: what can help your sore joint

Why does my joint feel worse this morning?

A worn joint often stiffens while you rest. The smooth surface inside it may be thinner. Nearby muscles may have lost some strength too. A tendon, a strong cord, connects muscle with bone. That cord can get sore when it works harder.

You'll often feel joint soreness deep where bones meet. Tendon soreness may sit beside the joint. It often grows when the attached muscle pulls. You won't always be able to tell them apart. An exam can tell whether the joint or tendon hurts.

Swelling can also block part of your bend. Clicks or grinding don't always mean new harm. Watch for more soreness, swelling or lost motion.

What can I do today without making it worse?

Move only as far as you can without sharp pain. Stop sooner if the joint swells more afterward. You'll often do better with short walks or easy reaches. Divide a big chore into several small jobs. Don't push through a growing limp.

Heat may ease stiffness before you move. Cold may calm swelling after a busy spell. A cane or brace can reduce some strain. Pain pills aren't safe for everyone. Kidney trouble, stomach bleeding or blood-thinning medicine may rule out some pills. Don't add one before asking your doctor.

Steady, gentle use is enough for today.

When is it time for an exam?

Book an exam when soreness changes your daily life. You may walk less or avoid the stairs. Perhaps the ache now wakes you at night. Your doctor will check the joint and nearby muscles. The exam may also find a sore tendon.

You'll have tests of strength, swelling and balance. An X-ray may show how worn the joint is. Bring records from any earlier visit. Tell the doctor which motion hurts and where. You'll then have a clearer reason for the soreness.

You'll discuss exercise, support, medicine or surgery. Ask which problem each choice is meant to help. Ask what risks matter with your health. You'll leave with a next step you understand.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. On 18 December 2024 FDA approved RYONCIL (remestemcel-L-rknd), the first mesenchymal stromal cell therapy ever approved in the United States - for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older, given as eight intravenous infusions. It is not an orthopedic product and does not make any joint injection approved.

   US Food and Drug Administration — FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. , 2024.

3. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

   United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.

4. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

5. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.